DECEMBER 5-9, 2023

CONCURRENT SPECIAL SESSIONS

Special Session 1: New Drug Approvals for Metastatic Breast Cancer, Hemisfair Ballroom 1-2

Moderators: Laleh Amiri-Kordestani, U.S. Food and Drug Administration, Silver Spring, Maryland and Martine J. Piccart, Institut Jules Bordet, Bruxelles, Belgium

Elacestrant

Mirat Shah, US Food and Drug Administration, Silver Spring, Maryland

Trastuzumab deruxtecan

Preeti Narayan, US Food and Drug Administration, Silver Spring, Maryland

Late breaking (new drugs currently under review)

Christy Osgood, US Food and Drug Administration, Silver Spring, Maryland

Panel Discussion

Panelists:

Janice Cowden, Metastatic Breast Cancer Alliance, Bradenton, Florida

Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

Vassiliki Karantza, Merck Research Laboratories, Rahway, New Jersey

Flora Mulkey, US Food and Drug Administration, Silver Spring, Maryland

Special Session 2: Prevention, Early Detection, and Interception, Stars at Night Ballroom 3-4

Moderator: Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

†Special Session 3: Social Determinants of Health: Impact on Cancer Care, Stars at Night Ballroom 1-2

Moderator: Amelie G. Ramirez, UT Health Science Center at San Antonio, San Antonio, Texas

What are social determinants of health and why are they important to cancer care?

Amelie G. Ramirez, UT Health Science Center San Antonio, San Antonio, Texas

Multilevel barriers to addressing social risks: Data from select NCI cancer settings

Brenda Adjei, National Cancer Institute, Bethesda, Maryland

How do hospitals/clinics utilize SDoH data?

Brian M. Rivers, Morehouse School of Medicine Cancer Health Equity Institute, Atlanta, Georgia

Once social determinants of health are determined, what processes need to be in place to reduce the burden on patients?

Sandi L. Pruitt, UT Southwestern Medical Center, Dallas, Texas

How is the impact of SDoH being evaluated at clinical/hospital and community levels?

Susan T. Vadaparampil, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Screening for health related social needs, and now what?

Barbara Segarra-Vazquez, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

Panel Discussion

†This session meets the Texas Medical Board criteria for formal continuing medical education involving the study of medical ethics and/or professional responsibility

CONCURRENT WORKSHOPS

Clinical Workshop: Tumor Agnostic Approaches to Care, Stars at Night Ballroom 1-2
Moderator: Sangeetha M. Reddy, UT Southwestern Medical Center, Dallas, Texas

Agnostic trials in the field of targeted therapies

Vivek Subbiah, UT MD Anderson Cancer Center, Houston, Texas

ADC development across tumor types

Joshua Z. Drago, Memorial Sloan Kettering Cancer Center, New York, New York

Real World Data

Mia A. Levy, Foundation Medicine, Inc., Cambridge, Massachusetts

Defining a biologic entity that is sensitive to immunotherapeutic

Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

Materials and Methods: Basic Science to Breast Oncology Workshop, Stars at Night Ballroom 3-4
Moderator: Neil Vasan, Columbia University Irving Medical Center, New York, New York

Organoid models of cancer and the tumor microenvironment

Calvin J. Kuo, Stanford University, Stanford, California

Modelling the effects of cell-cell interactions in the tumor microenvironment from single cell variability

Ashley M. Laughney, Weil Cornell Medicine, New York, New York

Real-world genomics

Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Virtual screening of ultra-large chemical spaces for novel chemotype discovery

John Irwin, University of California San Francisco, San Francisco, California

ED01: Latest Trends in Adjuvant Endocrine Therapy, Stars at Night Ballroom 3-4
Moderator: Fabrice André, Gustave Roussy, Villejuif, France

Optimizing endocrine therapy in premenopausal women

Vered Stearns, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

How to treat postmenopausal patients

Rachel Freedman, Dana-Farber Cancer Institute, Boston, Massachusetts

Who benefits from CDK 4/6 inhibitors and chemotherapy in the adjuvant setting

Otto Metzger, Dana-Farber Cancer Institute, Boston, Massachusetts

ED02: Lobular Breast Cancer, supported by the Lobular Breast Cancer Alliance, Stars at Night Ballroom 1-2
Moderator: Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Biological peculiarities of ILC

Christine Desmedt, KU Leuven, Leuven, Belgium

The challenges of lobular carcinoma

Tari A. King, Dana-Farber Cancer Institute, Boston, Massachusetts

Innovative approaches at the diagnosis and treatment of invasive lobular carcinoma

Jason Aboudi Mouabbi, UT MD Anderson Cancer Center, Houston, Texas

Panelist: Siobhán Freeney, European Lobular Breast Cancer Foundation, Dublin, Ireland

ED03: Overcoming Obesity-Associated Breast Cancer Risk, Hemisfair Ballroom 1-2
Moderator: Abenaa M. Brewster, UT MD Anderson Cancer Center, Houston, Texas

Breaking the obesity-breast cancer link: Comparing diet, drug and surgical approaches

Stephen D. Hursting, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Mechanisms for the effects of incretin and dual-incretin to produce substantial weight loss

Randy Seeley, University of Michigan, Ann Arbor, Michigan

Impact of exercise on breast cancer outcomes

Kerry S. Courneya, University of Alberta, Edmonton, Alberta, Canada

Panelist: 

ED04: Treatment Post-CDK 4/6 Inhibitors, Hemisfair Ballroom 3
Moderator: Stephanie Graff, Lifespan Cancer Institute, Providence, Rhode Island

Single agent endocrine therapy

Carlos H. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Combination endocrine therapy following progression on first-line therapy

Ruth O’Regan, University of Rochester, Rochester, New York

When to transition to cytotoxics

Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, Alabama

Panelist: Abigail Johnston, Surviving Breast Cancer, Orlando, Florida

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #1

PS01-01 Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study

Neslihan Cabıoğlu, Istanbul University, Istanbul, Turkey

PS01-02 Long-term outcomes of sentinel lymph node biopsy following neoadjuvant chemotherapy for initially node-positive breast cancer: A systematic review and meta-analysis.

Mariam Rana, University of Saskatchewan, Saskatoon, Canada

PS01-03 What to expect from the No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS] trial (KBCSG-21): Clinicopathologic characteristics and axillary lymph node status of enrolled patients

Jai Min Ryu, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

PS01-04 To dissect or not to dissect? The surgeon’s perspective on the prediction of ≥ 4 axillary lymph node metastasis in cN0 T1-2 breast cancer: A comparative analysis of the per-protocol population of the SINODAR-ONE clinical trial.

Damiano Gentile, IRCCS Humanitas Research Hospital, Rozzano MI, Italy

PS01-05 Discussant

Melissa Pilewskie, University of Michigan, Ann Arbor, Michigan

PS01-06 The relationship between margin status of <2mm and local recurrence in DCIS patients

Sarah Al Safi, Ministry of Health, Kuwait, Qatar

PS01-07 Impact of race and ethnicity on Recurrence risk in patients with ductal carcinoma in situ treated with breast-conserving surgery

Natália Polidorio, Memorial Sloan Kettering Cancer Center, New York, New York

PS01-08 Management of ipsilateral breast tumor recurrence following breast conservation surgery for ductal carcinoma in situ – a data-free zone

Brian Diskin, Memorial Sloan Kettering Cancer Center, New York, New York

PS01-09 Early results of a phase I pre-operative single fraction ablative trial for early stage breast cancer

Asal Rahimi, University of Texas Southwestern Medical Center, Dallas, Texas

PS01-10 Surgical margins in breast conserving surgery (BCS) for ductal carcinoma in-situ (DCIS) and clinical outcomes: significant associations with increased recurrence and overall survival.

John Robertson, University of Nottingham, Nottingham, United Kingdom; University Hospitals of Derby and Burton, Derby, United Kingdom

PS01-11 Discussant
Puneet Singh, The University of Texas MD Anderson Cancer Center, Houston, Texas

PS02 Improving QOL and Care Delivery for the Breast Cancer Patient, Hemisfair Ballroom 1-2

Moderator: Anne Blaes, University of Minnesota, Minneapolis, Minnesota

PS02-01 Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials

Lowell Hart, Wake Forest Baptist Health, Winston-Salem, North Carolina

PS02-02 Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS02-03 Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence and health-related quality of life in women with early breast cancer? An exploratory study

G. Bruce Mann, The Royal Melbourne Hospital, Melbourne, Australia

PS02-04 Associations of sleep health with quality of life among women with newly diagnosed breast cancer: baseline results from the AMBER cohort study

Lin Yang, Alberta Health Services, Edmonton, AB, Canada

PS02-05 Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
Paul Cottu, Institut Curie, Paris, France

PS02-06 Discussant
Don Dizon, Brown University, Providence, Rhode Island

PS02-07 Effectiveness of 24-week mobile application based human coaching program for controlling weight, BMI and body composition in overweight/obese breast cancer survivors: Single-arm prospective cohort study
So-Youn Jung, National Cancer Center, Goyang, Republic of Korea

PS02-08 The effect of a digital health coaching program on patient reported outcomes of women with breast cancer

Loretta A. Williams, The University of Texas MD Anderson Cancer Center, Houston, Texas

PS02-09 Nurse-led individualized follow-up versus regular physician-led visits after early breast cancer (MyHealth) - a randomized, controlled trial

Lena Saltbæk, Zealand University Hospital, Roskilde, Denmark

PS02-10 Discussant

Lindsay L. Peterson, Washington University in St Louis School of Medicine, St. Louis, Missouri

PS03 Insights from Single Cell, Spatial, and Artificial Intelligence Approaches, Stars at Night Ballroom 1-2
Moderator: Glenn Broeckx, Network of Antwerp Hospitals, Antwerpen, Belgium

PS03-01 Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients

Marit Otterlei Fjørtoft, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

PS03-02 Single-cell metabolic profiling uncovers new precision immunotherapy strategy in triple-negative breast cancer

Yi-Zhou Jiang, Fudan University Shanghai Cancer Center, Shanghai, China

PS03-03 The spatially resolved single-cell atlas of the tumor immune architecture revealed the central role of IFN-alpha and plasmacytoid dendritic cells in triple-negative breast cancer in the Mayo Clinic cohort and FinXX trial

Saranya Chumsri, Mayo Clinic, Jacksonville, Florida

PS03-04 Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer

Fabiana Napolitano, UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, Texas

PS03-05 Discussant

Ratna Vadlamudi, UT Health San Antonio, San Antonio, Texas

PS03-06 Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: saving costs and time (the CONFIDENT-B trial)

Carmen van Dooijeweert, University Medical Centre Utrecht, Utrecht, Netherlands

PS03-07 Morphometric signature identifies ductal carcinoma in situ of the breast with low risk of progression to invasive breast cancer

Marcelo Sobral-Leite, Netherlands Cancer Institute, Amsterdam, Netherlands

PS03-08 Spatial biomechanics determines fate in breast cancer

Sara Nizzero, Houston Methodist Research Institute, Houston, Texas

PS03-09 Age-related normal breast tissue features differ in women with germline BRCA1/2 mutations

Anita Grigoriadis, Breast Cancer Now Unit, King’s College London Faculty of Life Sciences and Medicine, London; School of Cancer and Pharmaceutical Sciences, King’s College London Faculty of Life Sciences and Medicine, London, United Kingdom

PS03-010 Discussant
Eugene Douglass, University of Georgia, Athens, Georgia

A Practical "How-To" Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Peer View Institute for Medical Education 

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of ER-Positive Metastatic Breast Cancer. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Research To Practice   

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Physicians' Education Resource, LLC

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #2 

PS04-01 Clinical impact of timing of systemic therapy in patients with early triple negative breast cancer

Stephan Seitz, University Medical Centre Regensburg, Regensburg, Germany

PS04-02 BRCA testing and PARP inhibitor utilization in real-world HER2-negative metastatic breast cancer

Siddhartha Yadav, Mayo Clinic, Rochester, Minnesota

PS04-03 Survival benefit of regional nodal irradiation in clinically node-positive breast cancer following neoadjuvant chemotherapy and breast-conserving surgery

Mahtab Vasigh, Department of surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

PS04-04 Adverse effects (AEs) reported via Patient Reported Outcome Measures (PROMs): A longitudinal analysis of the IMPORT HIGH breast radiotherapy trial (CRUK/06/003)

Sze Yi Ng, Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom

PS04-05 Discussant

Sarah Schellhorn Mougalian, Yale School of Medicine, New Haven Connecticut

PS04-06 Breast cancer recurrence among women with pre-diagnostic major depression and co-existing substance abuse disorder: A retrospective study in the United States Veterans Health Administration Cohort

Maya Aboumrad, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland and White River Junction VA Medical Center, White River Junction, Vermont

PS04-07 Associations between virtual care access and psychological and mental health conditions among adults with breast cancer in the US: A population-based analysis

Jincong Q. Freeman, University of Chicago, Chicago, Illinois

PS04-08 sociodemographic risk factors and prediction of aromatase inhibitor non-adherence in women with breast cancer enrolled in SWOG S1105

Dawn Hershman, Columbia University, New York, New York

PS04-09 Patient-reported benefit of resources designed to assist with the financial toxicity of breast cancer

Fumiko Chino, Memorial Sloan Kettering Cancer Center, New York, New York

PS04-10 Discussant

Claire Conley, Georgetown University, Washington, DC

PS05 Shining a New Light on Breast Cancer: Novel Molecular and Functional Imaging Approaches to Detect and Characterize Breast Cancer, Hemisfair Ballroom 1-2
Moderator: David Mankoff, University of Pennsylvania, Philadelphia, Pennsylvania

PS05-01 Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET/CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&02 study)

Zhixin Hao, Peking Union Medical College Hospital, Beijing, China

PS05-02 PET imaging of PARP expression as a biomarker of response to chemotherapy in breast cancer: A nonrandomized clinical trial

Sarah B. Gitto, University of Pennsylvania, Philadelphia, Pennsylvania

PS05-03 Magsense® HER2, a molecularly targeted magnetic resonance imaging agent for the detection of axillary nodal metastasis in subjects with human epidermal growth factor receptor 2 positive (HER2+) breast cancer

Isaac Bright, Imagion Biosystems Ltd, San Diego, California

PS05-04 [89Zr]Trastuzumab-PET/MRI to characterize her2+ breast cancer: A quantitative approach on tumor heterogeneity

Ameer Mansur, University of Alabama at Birmingham, Birmingham, Alabama

PS05-05 Discussant
Farrokh Dehdashti, Washington University in St. Louis, St Louis, Missouri

PS05-06 Outcomes of surveillance using contrast enhanced mammography in women with a personal history of breast cancer

Julia Matheson, Royal Melbourne Hospital and the University of Melbourne, Melbourne, Australia

PS05-07 Early prediction of response to neoadjuvant immunotherapy in triple negative breast cancer (TNBC) with DCE-MRI

Gaiane Rauch, The University of Texas MD Anderson Cancer Center, Houston, Texas

PS05-08 Restriction spectrum imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer

Maren Marie Sjaastad Andreassen, Department of Research and Innovation, Vestre Viken, Asker, Norway

PS05-09 A single-arm Phase II clinical study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer

Xiaohua Zeng, Chongqing University Cancer Hospital, Chongqing, China

PS05-10 Discussant

Amy Fowler, University of Wisconsin Madison, Madison, Wisconsin

PS06 Prognostic and Predictive Uses of Cell Free DNA, Stars at Night Ballroom 1-2
Moderator: Maggie Chon U Cheang, The Institute of Cancer Research, London, England

PS06-01 Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
Stephanie Graff, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, Rhode Island

PS06-02 Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
Lajos Pusztai, Yale University Cancer Center, New Haven, Connecticut

PS06-04 The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

Iseult M. Browne, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, England

PS06-08 Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort

Mitchell J. Elliott, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

PS06-05 Discussant

Ben H. Park, Vanderbilt University, Nashville, Tennessee

PS06-03 Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium
Emily L. Podany, Washington University in St. Louis, St. Louis, Missouri

PS06-06 Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer
Wolfgang Janni, University of Ulm, Germany

PS06-07 Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
Heather A. Parsons, Dana-Farber Cancer Institute; Harvard Medical School, Boston Massachusetts

PS06-09 Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies.

Marina N. Sharifi, University of Wisconsin, Madison, Wisconsin.

PS06-10 Discussant

David W. Cescon, Princess Margaret Cancer Centre/UHN, Toronto, Ontario, Canada

Welcome and Opening Remarks, Hall 1

Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

William L. Henrich, UT Health San Antonio, San Antonio, Texas

William L. McGuire Memorial Lecture, Hall 1

Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

Progress in the prevention of breast cancer

Jack Cuzick, Queen Mary University of London, London, England

GS01-01 Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: An exploratory analysis of CheckMate 7FL
Sherene Loi, Peter McCallum Cancer Centre, Melbourne, Australia

GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
Joyce O’Shaughnessy, Baylor University Medical Center, Dallas, Texas

GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial.
Michail Ignatiadis, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium

GS01-04 Discussant for GS01-01, GS01-02, and GS01-03

Laura Huppert, University of California, San Francisco

GS01-05 Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label phase 2 KEYLYNK-009 study
Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

GS01-06 Advancing evidence of the associations between specific benign breast diagnoses and future breast cancer risk
Olivia Sattayapiwat, University of California at Davis, Davis, California

GS01-07 Discussant for GS01-06

Anne Marie McCarthy, University of Pennsylvania, Philadelphia, Pennsylvania

GS01-08 CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
Eric Chang, Lester Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas

GS01-09 Discussant for GS01-08

Shom Goel, The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

GS01-10 HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
Sara Hurvitz, Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington

GS01-11 Discussant for GS01-10

Valentina Guarneri, Veneto Institute of Oncology IOV-IRCCS; University of Padua, Padua, Italy

Additional presentation to be announced

POSTER SESSION 1, Halls 2-3

Click title for full list of posters to be presented in this session.

RF01-01 SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer

John Robertson, University of Nottingham, Nottingham, United Kingdom; University Hospitals of Derby and Burton, Derby, United Kingdom

RF01-02 A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy:  evaluation of dermal safety, intra-mammary drug distribution, and biologic effects

Oukseub Lee, Northwestern University, Chicago, Illinois

RF01-03 PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study

Antonio Llombart-Cussac, Hospital Arnau de Vilanova, Valencia, Spain

RF01-04 Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification

Senthil Damodaran, The University of Texas MD Anderson Cancer Center, Houston, Texas

RF01-05 Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer

Elizabeth Harvey-Jones, King's College London  Great, Maze Pond, United Kingdom

RF01-06 Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer: a multicenter phase II trial based on a Bayesian adaptive randomized design

Hongnan Mo, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

RF01-07 The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2- breast cancer or TNBC

Sarina Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, Texas

RF01-08 A randomized, open-label phase III trial evaluating low-dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy- induced nausea and vomiting in solid tumors (OLAnzaPiNE)

Jyoti Bajpai, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India

Debate: Anthracyclines…To Give or Not to Give? Stars at Night Ballroom 1-2

Moderator: Harold J. Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts

 “For”

Martine J. Piccart, Institut Jules Bordet, Bruxelles, Belgium

“Against”

 Virginia F. Borges, University of Colorado Anshutz Medical Campus, Aurora, Colorado

State-of-the-Art Session 1: Immunotherapy: Purpose, Resistance, and Toxicity, Stars at Night Ballroom 3-4

Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

          Current overview of immunotherapy in breast cancer

          Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Biomarkers predicting immune related adverse events

Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts

Engineered T cell therapies- what is the outlook for breast cancer?

Valentina Hoyos Velez, Baylor College of Medicine, Houston, Texas

Chromosomal instability & resistance to immunotherapy

Kevin Litchfield, University College London, London, England

Molecular Tumor Board,  Hemisfair Ballroom 1-2

Moderator: Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Panelists:

Nicholas C. Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

Giuseppe Curigliano, European Institute of Oncology, Milan, Italy

Nancy U. Lin, Dana-Farber Cancer Institute, Boston, Massachusetts

Gaorav Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Sarah Eskreis-Winkler, Memorial Sloan Kettering Cancer Center, New York, New York

Maryam Shirazi, Tempus Labs, Inc., Chicago, Illinois

Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas

CONCURRENT EDUCATIONAL SESSION BLOCK #2

ED05: Controversies in Locoregional Care, Hemisfair Ballroom 1-2

Moderator: Debra Patt, Texas Oncology, Austin, Texas

Demystifying the Axilla: Challenging scenarios in the upfront surgery setting and after NAC

Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York

When less is more: Patient-friendly radiation courses with WBI and PBI

Icro Meattini, Università degli Studi di Firenze, Florence, Italy

Surgical management of Stage I TN and HER2+ breast cancer 

Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, New York

Optimizing outcomes: Breast reconstruction technique and timing after mastectomy   

Marco Maricevich, Baylor College of Medicine, Houston, Texas

Panelist: Jamie LaScala, Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, Pennsylvania

ED06: Coordinated Care of Brain Metastasis, Hemisfair Ballroom 3

Moderator: Carey K. Anders, Duke University Comprehensive Cancer Center, Durham, North Carolina

Co-presenters:

Rebecca Dent, National Cancer Centre Singapore, Singapore

Christopher D. Lascola, Duke University Medical Center, Durham, North Carolina

Nelson Moss, Memorial Sloan Kettering Cancer Center, New York, New York

Helen A. Shih, Massachusetts General Hospital, Boston, Massachusetts

Jeffrey Wefel, UT MD Anderson Cancer Center, Houston, Texas

ED07: HER2+ Breast Cancer: Updates from the Clinic and the Lab, Stars at Night Ballroom 1-2

Moderator: Mothaffar F. Rimawi, Baylor College of Medicine, Houston, Texas

Molecular determinates of response and resistance in HER2+ breast cancer

Ron Bose, Washington University School of Medicine in St. Louis St. Louis, Missouri

Recent advances in systemic disease

Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Novel systemic therapy strategies for HER2+ brain metastases

Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelist: Terlisa Sheppard, Terlisa Fights Breast Cancer, Inc., Florida

ED08: Toxicity Management: Next-Gen Therapies Means Next-Gen Toxicities, Stars at Night Ballroom 3-4

Moderator: Antonio C. Wolff, Johns Hopkins University, Baltimore, Maryland

Antibody drug conjugates

Heather L. McArthur, UT Southwestern Medical Center, Dallas, Texas

Next generation therapeutics in hormone positive breast cancer: Balancing efficacy and tolerability

Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

Immunotherapies – short and long term

Douglas B. Johnson, Vanderbilt University Medical Center, Nashville, Tennessee

Panelist: Sheila Johnson, Komen Advocates in Science, Swansea, Illinois

POSTER SESSION 2, Halls 2-3

Click title for full list of posters to be presented in this session.

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #3

Moderator: Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York

PS07-01 Exemestane and breast cancer prevention: how low can we go? Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative dosing regimen.
Davide Serrano, European Institute of Oncology IRCCS, Milan, Italy

PS07-02 Benign breast disease and microcalcifications in percutaneous biopsies and breast cancer risk
Sarah E. Schrup, Mayo Clinic, Rochester, Minnesota

PS07-03 Randomized trials of oestrogen-alone and breast cancer incidence: a meta-analysis
Joanne Mortimer, Comprehensive Cancer Center, City of Hope, Duarte, California

PS07-04 Improved uptake and adherence to prevention medication with use of baby tamoxifen in patients at high risk for breast cancer
Lauren Cornell, Mayo Clinic Florida, Jacksonville, Florida

PS07-05 Discussant

Pamela Goodwin, The Mount Sinai Hospital, New York, New York

PS07-06 A novel citrullinated-ENO1 peptide-based vaccine for triple-negative breast cancer prevention
Ricardo A. Leon Letelier, University of Texas MD Anderson Cancer Center, Houston, Texas

PS07-07 The RXR agonist, IRX4204, delays the formation of Brca1 mutant mammary tumors via modulation of the anti-tumor immune response
Cassandra Moyer, University of Texas MD Anderson Cancer Center, Houston, Texas

PS07-08 Bazedoxifene plus conjugated estrogen reduces mammary proliferation markers and improves adipocyte size, gut microbiome, and metabolic health: Findings from a preclinical model of obesity and breast cancer risk.
Erin D. Giles University of Michigan, Ann Arbor, Michigan

PS07-09 Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer
Per Lonning, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway

PS07-10 Discussant

Seema Khan, Northwestern University, Evanston, Illinois

PS08 Antibody Drug Conjugates: Where are We Headed? Hemisfair Ballroom 1-2

Moderator: Sarah Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts

PS08-01 Antibody-Drug Conjugates (ADCs) in breast cancer: Real world analysis of outcomes
Akshara Singareeka Raghavendra, University of Texas MD Anderson Cancer Center, Houston, Texas

PS08-02 Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
François Poumeaud, Oncopole Claudius Régaud IUCT-O, Toulouse, France

PS08-03 Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis
Rachel Occhiogrosso Abelman, Mass General Cancer Center/Dana-Farber Cancer Institute, Boston, Massachusetts

PS08-04 Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
Laura Huppert, University of California, San Francisco, California

PS08-05 Discussant

Ana C. Garrido-Castro, Dana-Farber/Brigham and Women’s Cancer Center; Harvard Medical School, Cambridge, Massachusetts

PS08-06 A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China

PS08-07 BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study.
Jiong Wu, Fudan University Shanghai Medical College, Shanghai, China

PS08-08 Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study
Yongmei Yin, Jiangsu Province Hospital, Nanjing, Jiagsu China

PS08-09 Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
Paolo Tarantino, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

PS08-10 Discussant

Kevin M. Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

PS09 Exploiting Tumor Biology in HER2-positive Breast Cancer to Escalate or De-escalate Neoadjuvant Therapy, Stars at Night Ballroom 1-2
Moderator: William Sikov, Women & Infants Hospital, Providence, Rhode Island

PS09-01 Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group
Monika Graeser, West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany; University Medical Center Hamburg, Hamburg, Germany

PS09-02 Event-free survival by Residual Cancer Burden (RCB) and intratumor her2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer
Otto Metzger, Dana-Farber Cancer Institute, Boston, Massachusetts

PS09-03 Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
Vicente Valero, University of Texas MD Anderson Cancer Center, Houston, Texas

PS09-04 The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial
Elisa Agostinetto, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.), Bruxelles, Belgium

PS09-05 Discussant

Jo Chien, University of California, San Francisco, California

PS09-06 Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer

Alberto Monroy Chargoy, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, Mexico

PS09-07 SPAG5 as a companion prognostic and predictive test for management of early stage HER2 positive breast cancer (BCs)
Tarek Tma Abdel-Fatah, Nottingham University Hospitals NHS TRUST, Nottingham, England

PS09-08 Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial
Maggie Chon U Cheang, The Institute of Cancer Research, London, England

PS09-09 Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer
Zhi-Ming Shao, Fudan University, Shanghai, China

PS09-10 Discussant

Marion van Mackelenbergh, Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

EXHIBITS CLOSE, Halls 2-3

Cases and Conversations™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Physicians' Education Resource, LLC 

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Research To Practice   

Mastering the Art of Precision in the Treatment of HR+ Early and Advanced Breast Cancer: A “How-To” Guide for Steering Through Increasing Complexity in Risk Assessment, Predictive/Prognostic Testing, and Selection/Sequencing of Standard-of-Care and Novel Therapies. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Peer View Institute for Medical Education

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #4 

PS10 Refining Prediction of Cancer Risk and Outcomes, Stars at Night Ballroom 3-4
Moderator: Fergus J. Couch, Mayo Clinic, Rochester, Minnesota

PS10-01 Hormonal contraception and breast cancer risk for carriers of germline pathogenic variants in BRCA1 and BRCA2
Kelly-Anne Phillips, Peter MacCallum Cancer Centre, Melbourne, Australia

PS10-02 Association between germline mutation status and overall survival among women with breast cancer in population-based studies in the United States
Siddhartha Yadav, Mayo Clinic, Rochester, Minnesota

PS10-03 Impact of baseline oestradiol and testosterone on the preventive effect of anastrozole
Jack M. Cuzick, Queen Mary University of London, England

PS10-04 The landscape of somatic genetic alterations in breast cancers from carriers of germline pathogenic variants in DNA-repair genes
Siddhartha Yadav, Mayo Clinic, Rochester, Minnesota

PS10-05 Discussant

Banu K. Arun, UT MD Anderson Cancer Center, Houston, Texas

PS10-06 Contribution of a breast cancer polygenic risk score to mammography artificial intelligence models and breast density for long term breast cancer risk prediction

Celine M. Vachon, Mayo Clinic, Rochester, Minnesota

PS10-07 A second-generation polygenic risk score PRS based on genetic ancestry improves breast cancer BC risk prediction for all ancestries

Timothy Simmons, Myriad Genetics, Inc, Salt Lake City, Utah

PS10-08 Validation of a clinical image-based AI-risk model for individualized breast cancer screening in a multi-national setting
Mikael Eriksson, Karolinska Institutet, Stockholm, Sweden

PS10-09 Development of an absolute risk prediction model for premenopausal breast cancer in an international consortium
Kristen D. Brantley, Harvard TH Chan School of Public Health, Boston, Massachusetts

PS10-10 Discussant
Per Hall, Karolinska Institutet, Stockholm, Sweden

PS11 CNS Disease in Breast Cancer: Where are We Now and Can We do Better? Hemisfair Ballroom 1-2
Moderator: Erica Stringer-Reasor, University of Alabama at Birmingham/O'Neal Comprehensive Cancer Center, Birmingham, Alabama

PS11-01 Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients

Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, Massachusetts

PS11-02 Clinical risk factors of Central Nervous System CNS-related death in patients with HER2-positive metastatic breast cancer
Emanuela Ferraro, Memorial Sloan Kettering Cancer Center, New York, New York

PS11-03 Comparison of next-generation sequencing NGS results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer MBC and leptomeningeal disease LMD
Laura Huppert, University of California, San Francisco, California

PS11-04 Discussant

Aki Morikawa, University of Michigan School of Medicine, Ann Arbor, Michigan

PS11-05 Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: Results from cohort 5 of the DEBBRAH study
Marta Vaz Batista, Hospital Professor Doutor Fernando Fonseca EPE, Lisbon, Portugal. Medica Scientia Innovation Research MEDSIR, Barcelona, Spain and Ridgewood, New Jersey, United States

PS11-06 Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival
Alyssa M. Pereslete, Herbert Wertheim College of Medicine, Miami, Florida, and Dana-Farber Cancer Institute, Boston, Massachusetts

PS11-07 High prevalence of HER2-Low and AR expression in breast cancer brain metastases provide novel therapeutic options
Guadalupe Garcia, Vanderbilt University Medical Center, Nashville, Tennessee

PS11-08 Discussant

Naoki Niikura, Tokai University School of Medicine, Tokyo, Japan

PS12 Putting Brakes on the Cell Cycle: Understanding Mechanisms Governing CDK 4/6 inhibitor Resistance and Role for Novel Therapeutic Strategies, Stars at Night Ballroom 1-2
Moderator: Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

PS12-02 Exploration of ctDNA Dynamics in the PACE trial: A randomized phase ii study of fulvestrant, palbociclib, and avelumab for HR+/HER2- metastatic breast cancer

Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

PS12-03 p53 loss enables HR+ breast cancer escape from CDK4/6 inhibitor-induced quiescence via CDK2

Rei Kudo, Memorial Sloan Kettering Cancer Center, New York, New York

PS12-04 Inhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer.

Maria Teresa Herrera Abreu, Institute of Cancer Research

PS12-05 Discussant

Eneda Toska, Johns Hopkins University School of Medicine, Baltimore, Maryland

PS12-06 A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer

Shom Goel, The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

PS12-07 Phase II clinical trial of palbociclib and binimetinib in advanced triple-negative breast cancer (TNBC) with hyperactivation of ERK and/or CDK4/6

Miguel Quintela-Fandino, CNIO - Spanish National Cancer Research Center, Madrid, Spain

PS12-08 MORPHEUS hormone receptor-positive breast cancer: interim analysis of a phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease

Kyung Hae Jung, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

PS12-09 Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292

Barbara Pistilli, Gustave Roussy, Villejuif, France

PS12-10 Discussant

Richard Finn, University of California Los Angeles, Los Angeles, California

General Session 2, Hall 1

GS02-01 Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2- breast cancer: Results from TROPION-Breast01
Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
Giacomo Montagna, Memorial Sloan Kettering Cancer Center, New York, New York

GS02-03 Discussant for GS02-02

Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts

GS02-04 Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival
Kelly Metcalfe, University of Toronto, Toronto, Ontario, Canada

GS02-05 Overview of axillary treatment in early breast cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
Gurdeep S. Mannu, University of Oxford, Oxford, England

GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.
Jana de Boniface, Karolinska Institutet, Stockholm, Sweden;Capio St. Göran’s Hospital, Stockholm, Sweden

GS02-07 Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304
Eleftherios Mamounas, Orlando Health Cancer Institute, Orlando, Florida

GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
Reshma Jagsi, Emory University, Atlanta, Georgia

GS02-09 Discussant for GS02-06, GS02-07, and GS02-08

Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York

GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Anne M. May, University Medical Center, Utrecht, Netherlands

GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Hatem A. Azim, Jr., Monterrey Institute of Technology, Monterrey, Mexico

GS02-12 Discussant for GS01-11

Hee Jeong Kim, Asan Medical Center, Seoul, Republic of Korea

GS02-13 Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study
 Matteo Lambertini, University of Genova - San Martino Hospital, Genova, Italy 

Plenary Lecture 1, Hall 1

Moderator: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

Breast cancer evolution, immune evasion and metastasis driven by chromosomal instability

RF02-01 A multicenter, phase i/ii trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (hr)-positive, HER2-positive metastatic breast cancer (ASPIRE)

Amy Tiersten, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York

RF02-02 BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kα activity without affecting glucose metabolism

Pedro Beltran, BridgeBio Pharma Oncology Therapeutics, Orinda, California

RF02-03 Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

RF02-04 A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer (JCOG1607 HERB TEA study)

Akihiko Shimomura, National Center for Global Health and Medicine, Tokyo, Japan

RF02-05 Report on cohort expansion of phase i study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 low breast cancer

Pamela Munster, University of California San Francisco, San Francisco, California

RF02-06 AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)

Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

RF02-07 Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC

Claudio Vernieri, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

POSTER SESSION 3, Halls 2-3

Click title for full list of posters to be presented in this session.

Clinical Case Discussions, Stars at Night Ballroom 3-4

Moderator: Matthew P. Goetz, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Panelists:

Fabrice André, Gustave Roussy, Villejuif, France

Nadia Harbeck, LMU University Hospital, Munich, Germany

Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

Aleix Prat, Hospital Clínic Barcelona, Barcelona, Spain

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Samilia Obeng-Gyasi, The Ohio State University, Columbus, Ohio

Lori Pierce, University of Michigan, Ann Arbor, Michigan

Bev Saltzman Lewyn, Patient Advocate, Atlanta, Georgia

State-of-the-Art Session 2: Implications of Senescence for Breast Cancer Biology and Treatment, Hemisfair Ballroom 1-2

Moderator: Justin M. Balko, Vanderbilt University, Nashville, Tennessee

Cellular senescence: The senescence-associated secretory phenotype (SASP) and immunity

Marcus Ruscetti, UMass Chan Medical School, Worcester, Massachusetts

Implications of therapy induced senescence in breast cancer

James G. Jackson, Tulane University School of Medicine, New Orleans, Louisiana

Influence clinical trial and new therapeutics

Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia

Clinical Controversies, Stars at Night Ballroom 3-4

Moderator: Lisa A. Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Are we ready to stop staging the axilla?

Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York

Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, California

How to treat small triple negative breast cancer

Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas

Alexandra Thomas, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Biology or stage? Tailoring treatment for premenopausal women with nodal involvement, but low genomic prognostic assay

Eric P. Winer, Yale Cancer Center, New Haven, Connecticut

Kevin M. Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

CONCURRENT EDUCATIONAL SESSION BLOCK #3

ED09: Genomics for Clinical Research and Cancer Care, Stars at Night Ballroom 1-2

Moderator: Norah Lynn Henry, Rogel Cancer Center University of Michigan, Ann Arbor, Michigan

Emerging approaches to targeting pathways using precision medicine in breast cancer

Milan Radovich, Caris Life Sciences, Irving, Texas

Tumor tissue vs. ctDNA

Ben O'Leary, Royal Marsden Hospital, London, England

When do you order and how to interpret genomic testing

Jorge S. Reis-Filho, AstraZeneca, Gaithersburg, Maryland

ED10: PI(3)king the Right Target, Stars at Night Ballroom 3-4

Moderator: Cynthia X. Ma, Washington University Siteman Cancer Center, Saint Louis, Missouri

PI3 Kinase

Neil Vasan, Columbia University Irving Medical Center, New York, New York

Identifying collateral vulnerabilities in the AKT pathway for therapeutic benefit

Alex Toker, Beth Israel Deaconess Medical Center, Boston, Massachusetts

mTOR pathway

Robert J. Schneider, NYU Grossman School of Medicine, New York, New York

ED11: Inflammatory Breast Cancer: Clinical Challenges, Evolving Concepts and Novel treatments (People’s Choice), Hemisfair Ballroom 1-2

Moderator: Filipa Lynce, Dana-Farber Cancer Institute, Boston, Massachusetts

Is IBC a genomically different type of BC?

Frederick Howard, University of Chicago, Chicago, Illinois

Surgical controversies in IBC

Anthony Lucci, UT MD Anderson Cancer Center, Houston, Texas

Approaches to radiation therapy for inflammatory breast cancer

Jennifer Bellon, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelists:

Terry Arnold, The IBC Network Foundation, Sealy, Texas  

Naomi John, IBC Network UK, Stratford-upon-Avon, United Kingdom

Ginny Mason, Inflammatory Breast Cancer Research Foundation, Broadway, Virginia

POSTER SESSION 4, Halls 2-3

Click title for full list of posters to be presented in this session

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #5

Moderator: Kimberley Lee, Moffitt Cancer Center, Tampa, Florida

PS13-01 Worse prognosis for breast cancer in the second and third trimesters and shortly postpartum: An update of the Dutch pregnancy-associated breast cancer cohort
Carmen Van Dooijeweert, University Medical Center Utrecht, Utrecht, Netherlands

PS13-02 Clinical outcome and patients’ characteristics of breast cancer diagnosed during pregnancy: A retrospective single institutional study
Kausar Suleman, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

PS13-03 Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: an international cohort study
Ana S. Ferrigno, Yale University School of Medicine, New Haven, Connecticut

PS13-04 Frequent Intra-tumoral hypoxia in pregnancy-associated breast cancer
Carsten F.J Bakhuis - University Medical Center Utrecht, Utrecht, Netherlands

PS13-05 Moved to GS2-13

PS13-06 Discussant

Virginia F. Borges, University of Colorado Anschutz Medical Center

PS13-07 Systemic therapy in geriatric patients with triple negative breast cancer: a National Cancer Database analysis
Ana Sandoval-Leon, Miami Cancer Institute, Miami, Florida

PS13-08 Chemotherapy in geriatric patients with early stage HER2+ breast cancer: A National Cancer Database analysis.

Reshma Mahtani, Miami Cancer Institute, Miami, Florida

PS13-09 Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men.

Dario Trapani, European Institute of Oncology, IRCCS, University of Milano, Milan, Italy

PS13-10 Discussant

Mina Sedrak, UCLA Health, Los Angeles, California

PS14 Setting Expectations for Toxicities Related to I/O Therapy, Hemisfair Ballroom 1-2
Moderator: William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States

PS14-01 Immune related adverse events in patients ≥65 years vs. <65 years with breast cancer treated with immunotherapy

Neelima Vidula, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

PS14-02 Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522
Mara Hofherr, Washington University in St. Louis, St. Louis, Missouri

PS14-03 Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Saya Jacob, University of California, San Francisco, California

PS14-04 Discussant

Yuan Yuan, Cedars-Sinai Cancer Center, Los Angeles, California

PS14-05 Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain & Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain

PS14-06 Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522

Mara Hofherr, Washington University in St. Louis, St. Louis, Missouri

PS14-07 Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial

Hanna Hübner - Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

PS14-08 Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

PS14-09 Discussant

Ricardo Costa, H. Lee Moffitt Cancer Center, Tampa, Florida

PS15 Novel Nuclear Receptor Targeting Therapies, Stars at Night Ballroom 1-2
Moderator: Lajos Pusztai, Yale University Cancer Center, New Haven, Connecticut

PS15-01 A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/ HER2- locally advanced or metastatic breast cancer

Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China

PS15-02 A Phase Ⅰb Study of D-0502 as monotherapy for advanced or metastatic ER-positive and HER2-negative breast cancer: Results from the dose-expansion stage

Kate Lathrop, UT Health Science Center at San Antonio, San Antonio, Texas

PS15-03 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort

Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee

PS15-04 A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients

Arlene Chan, Breast Cancer Research Centre – Western Australia, Hollywood Consulting Centre, Nedlands, Australia

PS15-05 Discussant

Bora Lim, University of Texas MD Anderson Cancer Center, Houston, Texas

PS15-06 Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction

Rebecca A. Burrell, University of Cambridge, Cambridge, United Kingdom

PS15-07 Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study

Hui-Ping Li, Peking University Cancer Hospital & Institute, Beijing, China

PS15-08 Final Overall Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer.

Marcus Vetter, Cancer Center Baselland, Basel-Landschaft, Switzerland

PS15-09 Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study

Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

PS15-10 Discussant

Giampaolo Bianchini, IRCCS Ospedale San Raffaele, Milan, Italy

EXHIBITS CLOSE, Halls 2-3

Beyond the Guidelines: Clinical Investigator Perspectives on theManagement of HER2-Low Breast Cancer. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Research To Practice              

Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care. An independent satellite symposium held in conjunction with the 46th annual San Antonio Breast Cancer Symposium® presented by Clinical Care Options

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #6

PS16-01 Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) – final analysis of the neoadjuvant neoMono trial
Hans-Christian Kolberg, Marienhospital Bottrop, Bottrop, Germany

PS16-02 Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Maria Gión, Hospital Ruber Internacional, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain

PS16-03 Intratumoral dosing of INT230-6 in early-stage breast cancer patients induces tumor cell necrosis and immunomodulatory effects: A phase ii randomized window-of-opportunity study – the INVINCIBLE trial
Angel Arnaout, Ottawa Hospital/Ottawa Hospital Research Institute/Ontario Institute of Cancer Research, Ottawa, Ontario, Canada

PS16-04 Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)
Andrea Vethencourt, Institut Català d'Oncologia, Oncology Department, Barcelona, Spain. Insitut d’Investigació Biomèdica Bellvitge (IDIBELL), Barcelona, Spain

PS16-05 Discussant

Sangeetha Reddy, UT Southwestern Medical Center, Dallas, Texas

PS16-06 Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study
Min Ji Kim, Gangnam Severance Hospital, Gangnam, Republic of Korea

PS16-07 Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy
Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

PS16-08 Histologic pattern and outcomes in high-grade metaplastic breast cancer compared to triple-negative ductal breast cancer counterparts: A single institution retrospective study
Ashley Matusz-Fisher, McLaren Healthcare, Charlevoix, Michigan

PS16-09 Analysis of the Radiosensitivity Index/Genomic-Adjusted Radiation Dose (RSI-GARD) in paired pre- and post-treatment TNBC samples: Implications for biomarker-guided radiotherapy
Shane R. Stecklein, University of Kansas Medical Center; Kansas Institute for Precision Medicine, Kansas City, Kansas

PS16-10 Spatial immune cell distribution can refine prognosis in early-stage ER+/HER2-/LN- breast cancer
Zak Kinsella, Royal College of Surgeons in Ireland, Dublin, Ireland

PS16-11 Discussant

Christos Vaklavas, Huntsman Cancer Institute, Salt Lake City, Utah

PS17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approaches, Hemisfair Ballroom 1-2

Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

PS17-01 Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Jackson Liang, Genentech, Inc., San Francisco, California

PS17-02 Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Janice Lu, Northwestern University Lurie Comprehensive Cancer Center, Chicago, Illinois

PS17-03 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial
Sacha J. Howell, The University of Manchester, Manchester, England

PS17-04 Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches
Angel Guerrero-Zotano, Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain, and GEICAM Spanish Breast Cancer Group, San Sebastian, Spain

PS17-05 Discussant

Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

PS17-06 A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
Cynthia Ma, Washington University in St. Louis, St. Louis, Missouri

PS17-07 Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: A Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer
Einav Gal-Yam, Breast Oncology Institute Sheba Medical Center, Ramat Gan, Israel

PS17-08 A Phase Ib Study to evaluate the efficacy and safety of afuresertib plus fulvestrant in patients with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

PS17-09 An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer
Yasuaki Uemoto, UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas

PS17-10 Discussant

Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

PS18 Disparate Care calls for Desperate Measures:  Understanding Gaps in Quality of Care and Opportunities to Improve it, Stars at Night Ballroom 1-2
Moderator: Debra Patt, Texas Oncology, Dallas, Texas

PS18-01 Stage advancement and the rate of growth associated with preoperative delay in patients having breast cancer
Richard J. Bleicher, Fox Chase Cancer Center, Philadelphia, Pennsylvania

PS18-02 Prevalence of refusal of recommended cancer treatments and survival differences in breast cancer patients: analysis of the national cancer database
Jincong Q. Freeman, University of Chicago, Chicago, Illinois

PS18-03 The association between food deserts, food swamps, and postmenopausal breast cancer mortality in the United States
Malcolm Bevel, Augusta University, Augusta, Georgia

PS18-04 Racial disparities in breast cancer and effect of obesity: MammaPrint, BluePrint and whole transcriptome analyses of tumors in Latin American patients in FLEX trial
Marcela Mazo-Canola, Mays Cancer Center, San Antonio, Texas

PS18-05 Discussant

Lia Scott, Georgia State University School of Public Health

PS18-07 Trends in guideline concordant care for inflammatory breast cancer: an analysis of the national cancer database
Brian Diskin, Memorial Sloan Kettering Cancer Center, Atlanta, Georgia

PS18-08 Bridging disparities in survivorship care: Leveraging telehealth for diverse patients in safety net hospital
Ivan C. Leung, University of California, San Francisco, California

PS18-09 The DARC side of breast cancer - DARC, Duffy-null and African ancestry influence in the Triple Negative Breast Cancer tumor microenvironment
Rachel Martini, Morehouse School of Medicine, Atlanta, Georgia

PS18-10 Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the northern California breast cancer family registry
Julia D. Ransohoff, Stanford University School of Medicine, Stanford, California

PS18-11 Discussant

Kathryn Hudson, Texas Oncology, San Antonio, Texas

General Session 3, Hall 1  

GS03-01 Magnetic Resonance Imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ: 5-year clinical outcomes of E4112
Seema Khan, Northwestern University, Evanston, Illinois

GS03-02 Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
Janet A. Dunn, University of Warwick, Coventry, England

GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, Texas

GS03-04 Novel mechanisms of CDH1 inactivation in breast invasive lobular carcinoma unveiled by the integration of artificial intelligence and genomics
Fresia Pareja, Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

GS03-05 Discussant for GS03-04

Frederick M. Howard, University of Chicago, Chicago, Illinois

GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
Nicholas C. Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

GS03-07 Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.
Daniel Stover, Ohio State University Comprehensive Cancer Center, Columbus, Ohio

GS03-08 Discussant for GS03-07

Christos Sotiriou, Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium

GS03-09 Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
Nolan Priedigkeit, Dana-Farber Cancer Institute / Broad Institute of MIT and Harvard, Boston, Massachusetts

GS03-10 Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
Andreas Varkaris, Massachusetts General Hospital, Boston, Massachusetts

GS03-11 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
Christina Curtis, Stanford University, Stanford, California

GS03-12 Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany

Plenary Lecture 2, Hall 1  

Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

Recent advances in triple negative breast cancer

Melinda L. Telli, Stanford University School of Medicine, Stanford, California

Moderators: Evanthia Roussos Torres, University of Southern California, Los Angeles, California and Nicholas C. Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

LBO1-01 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Peter Schmid, Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, United Kingdom

LBO1-02 Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
Luca Gianni, Fondazione Michelangelo, Milan, Italy

LBO1-03 Randomized Phase II Study of Neoadjuvant Nivolumab (N)  2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)
Nicholas Zdenkowski, Breast Cancer Trials, Newcastle, NSW, Australia

LBO1-04 Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

Santiago Escrivá-de-Romani, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

LBO1-05 Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)

Oleg Gluz, West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany

Question & Answer

POSTER SESSION 5, Halls 2-3

Click title for full list of posters to be presented in this session

AACR Outstanding Investigator Award for Breast Cancer Research, supported by the Breast Cancer Research Foundation, Stars at Night Ballroom 1-2
Alana L. Welm, Huntsman Cancer Institute, Salt Lake City, Utah

Translational Research Controversies, Stars at Night Ballroom 3-4

Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

Topic 1: Baby-TAM

Per Hall, Karolinska Institutet, Stockholm, Sweden

Jack Cuzick, Queen Mary University of London, London, England

Topic 2: When to do a window trial

Mitchell Dowsett, Royal Marsden Hospital, London, England

Sara A. Hurvitz, Fred Hutchinson Cancer Center/University of Washington, Seattle, Washington

Topic 3: Are we sequencing too late?

Charles M. Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Fabrice André, Gustave Roussy, Villejuif, France

State-of-the-Art Session 3: Targeting Mutant ER, Hemisfair Ballroom 1-2
Moderator: Aditya Bardia, Massachusetts General Hospital, Boston, Massachusetts

SERMs versus SERDs for targeting ESR1 mutations

Geoffrey L. Greene, University of Chicago, Chicago, Illinois

Tracking mutant ER using ctDNA

François-Clément Bidard, Institut Curie, Paris, France

The future of oral SERDs

Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee

BREAK  

BREAK

Exhibits Close, Hall 2-3

Moderator: Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelists:

William Barlow, University of Washington, Seattle, Washington

Javier Cortes Castan, Ramón y Cajal University Hospital, Madrid, Spain

Lesley Glenn, Project Life, Central Point, Oregon

Heather L. McArthur, UT Southwestern Medical Center, Dallas, Texas

Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas

Richard C. Zellars, Indiana University School of Medicine, Indianapolis, Indiana

Alastair M. Thompson, Baylor College of Medicine, Houston, Texas

Career Development Forum

Planning Your First Clinical Trial, Room 302
Moderator: Brenda J. Ernst, Mayo Clinic, Phoenix, Arizona

This workshop for residents, fellows, and early-stage clinical faculty will consist of presentations on key factors to consider when planning your first clinical trial followed by a 30-minute panel discussion. 

Overview and background: What makes a good clinical protocol?

Brenda J. Ernst, Mayo Clinic, Phoenix, Arizona

Designing with clinical trial eligibility in mind

Ruth O’Regan, University of Rochester, Rochester, New York

What are the most important statistical considerations for a protocol?

Thomas Braun, University of Michigan, Ann Arbor, Michigan

Importance of informed consent

Dawn L. Hershman, Columbia University Medical Center, New York, New York

Engaging and including patient advocates in protocol development

Carole Baas, NCI Physical Sciences in Oncology Network, Southlake, Texas

The value of collaboration: How to get involved in cooperative groups as an early researcher

Andrew Brenner, UT Health Science Center at San Antonio, San Antonio, Texas

Q&A/Discussion

Grant Writing Tips and Tricks, Room 303

Moderator: Pooja Advani, Mayo Clinic Florida, Jacksonville, Florida

This workshop for graduate students, fellows, and early-stage faculty will consist of presentations with expert grant writers and reviewers followed by a 30-minute panel discussion.

Choosing the right mechanism and navigating the grant application process

David Gius, Mays Cancer Center at UT Health San Antonio, San Antonio, Texas

Strategies to communicate your project through your grant writing

Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

Navigating the NIH peer review process

Dolores Arjona, Center for Scientific Review - National Institutes of Health, Bethesda, Maryland

Engaging the right support: From industry to cooperative groups

Minetta Liu, Natera, San Carlos California

Q&A/Discussion

Navigating Success: Women’s Career Development (pre-registration required, session full), Room 304

Supported by Gilead Sciences, Seagen, and Victoria's Secret/Pelotonia

Moderator: Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts

Designed for women who have completed their training and are now in practice, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, provide mentorship, and discuss strategies to overcome gender-related challenges in the field of cancer research. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a stronger support network, and acquire practical tools to thrive and excel in their scientific research careers.

9:00 am - 11:00 am Presentations and Panel Discussions

Setting the stage for success
Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts

Running up that hill - Experiences of a female scientist
Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Evidence-based strategies to address systemic barriers facing women researchers
Reshma Jagsi, Emory University, Atlanta, Georgia

Navigating a path in cancer research as underrepresented minority women
Amelie Ramirez, UT Health Science Center at San Antonio, San Antonio, Texas

Panel Discussion

11:00 am - 11:15 am Break

11:15 am - 12:00 pm Workshop
Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts